COgnitioN With VERiciGuat Evaluation in Heart Failure
Key facts
- Where
- Calgary, Edmonton, Montreal, and Ottawa, CanadaSee the 4 sites
- Phase
- Phase 2
Where in Canada
- University Of CalgaryCalgary, CanadaTaking people
- University of AlbertaEdmonton, CanadaTaking people
- McGill University Health CenterMontreal, CanadaNot yet recruiting
- University of OttawaOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alberta
- Trial code
- NCT06601465
- Record updated
- 25 August 2026
- Original description
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.Read full original descriptionShow less
CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.
Inclusion: Adult patients; Established chronic heart failure (≥ 6 months); Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).
Exclusion: Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding); General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures [coronary angioplasty and/or surgical revascularization in the previous 3 months], cancer/malignancy, or with severe dementia); CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias); Patients with allergies to the study products; Unable to undergo CMR imaging or brain MRI; Patients currently hospitalized.